Search

Displaying results 2661 - 2670 of 10000 in total
  1. Drug

    Calcium lactate gluconate

    go.drugbank.com/drugs/DB13365
    Investigational

    Mixtures: CALCIUM SANDOZ FORTE 300 MG/2940 MG EFERVESAN TABLET, 20 ADET, CALSOURCE 500 MG (EFFERVESCENT TABLETS)
  2. Drug

    MK-0752

    go.drugbank.com/drugs/DB12852
    Investigational

    Mk 0752 is under investigation in clinical trial NCT00572182 (MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer).

  3. Drug

    Bfpet F-18

    go.drugbank.com/drugs/DB15424
    Investigational

    Bfpet F-18 is under investigation in clinical trial NCT03265431 (Evaluation of PET/MR in Patients Selected for Ablation Therapy).

    Synonyms: Bfpet F-18
  4. Drug

    Rurioctocog alfa pegol

    go.drugbank.com/drugs/DB16007
    ApprovedInvestigational

    [L40119] Rurioctocog alfa pegol is a covalent conjugate of [octocog alfa], which is a recombinant factor VIII produced by recombinant DNA technology from a Chinese hamster ovary cell line. … Bleeding in joints is a common manifestation of hemophilia A, and bleeding episodes can be severe and life-threatening like intracranial hemorrhage.

    Synonyms: Antihemophilic factor (recombinant), pegylated (20 kda), Antihemophilic factor (recombinant), pegylated (mw 20000)
  5. Drug

    Tienilic acid

    go.drugbank.com/drugs/DB04831
    ApprovedWithdrawn

    It was withdrawn in 1982 after case reports in the United States suggested a link between ticrynafen and hepatitis. (Manier et al., 1982) … Tienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension.

    Synonyms: (2,3-Dichloro-4-(2-thenoyl)phenoxy)acetic acid, 4-(2-Theonyl)-2,3-dichlorphenoxyessigsäureCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  6. Drug

    MM-111

    go.drugbank.com/drugs/DB17983
    Investigational

    MM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.

  7. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]

    Synonyms: 6-(4-((1S,3S)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one
  8. Drug

    Paltimatrectinib

    go.drugbank.com/drugs/DB21588
    Investigational

    Paltimatrectinib is under investigation in clinical trial NCT04901806 (Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors). … Paltimatrectinib is a small molecule drug. The usage of the INN stem '-trectinib' in the name indicates that Paltimatrectinib is a tropomyosin receptor kinase (TRK) inhibitor.

  9. Drug

    Resolvin E1

    go.drugbank.com/drugs/DB13105
    Investigational

    Resolvin E1 (RX 10001) is under investigation in clinical trial NCT00941018 (Single and Multiple Ascending Oral Dose Study of Resolvin E1 in Healthy Volunteers).

    Categories: Fatty Acids, Omega-3
  10. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [L42330] It is a 900 kDa multimeric complex comprising a 150 kDa toxin, a 130 kDa non-toxic non-haemagglutinating protein, and various other haemagglutinins. … [A249920] LetibotulinumtoxinA is a type A botulinum neurotoxin produced from fermentation of _Clostridium botulinum_ strain CBFC26.

    Synonyms: BoNT/A-DSCategories: Botulinum Toxins, Type A